海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- A study of REGN2810 (Cemiplimab, Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy versus pembrolizumab in patients with lung cancer
- Non-Small Cell Lung Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Serbia, Slovakia, South Africa, Sweden, Switzerland, United Kingdom, United States
- 2018-04-17
Authorised
- A study of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy versus pembrolizumab in patients with lung cancer
- Non-Small Cell Lung Cancer;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Canada, Croatia, Czech Republic, Denmark, Finland, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Serbia, Slovakia, South Africa, Sweden, Switzerland, United Kingdom, United States
- 2018-03-08
Authorised
- Estudio abierto y aleatorizado para evaluar la eficacia radiológica y la seguridad de Enbrel® (etanercept) añadido a metotrexato en comparación con el tratamiento habitual en pacientes con artritis reumatoide moderada An Open-Label, Randomized Study To Evaluate The Radiographic Efficacy And Safety Of Enbrel™ (Etanercept) Added To Methotrexate In Comparison With Usual Treatment In Subjects With Moderate Rheumatoid Arthritis Disease Activity. - Extra
- Artritis reumatoide RHEUMATOID ARTHRITIS MedDRA version: 9.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis
- Austria, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Spain, United Kingdom
- 2008-03-24
Authorised
- A randomized, multinational, double-blind, placebo-controlled, parallel-group design pilot study to estimate the tolerability, safety, pharmacokinetics, and pharmacodynamic effects of teriflunomide for 24 weeks when added to treatment with glatiramer acetate in subjects with multiple sclerosis
- Multiple sclerosis
- Austria, Germany, Italy, United Kingdom
- 2006-12-17
Authorised
- A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)
- Mild to Moderate Alzheimer's Disease MedDRA version: 8.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease
- Austria, Bulgaria, Estonia, Germany, Greece, Hungary, United Kingdom
- 2006-11-23
Authorised
- Natalizumab de-escalation to interferon-beta-1b in patients with relapsing-remitting multiple sclerosis: A multicenter study
- relapse-remitting multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Austria, Switzerland
- 2013-03-12
Authorised
- Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
- Healthy adults;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
- Austria
- 2015-10-22
Authorised
- Research study comparing insulin degludec to insulin detemir, together with insulin aspart, in pregnant women with type 1 diabetes
- Diabetes Mellitus, Type 1 MedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 100000004861 ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Australia, Austria, Brazil, Canada, Denmark, European Union, Greece, Ireland, Israel, Russian Federation, Serbia, Spain, United Kingdom
- 2017-07-19
Authorised
- Safety and Efficacy Study of Bosutinib in Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with one or two more Tyrosine Kinase Inhibitors
- Philadelphia Chromosome Positive Chronic Myeloid Leukaemia MedDRA version: 20.0 Level: PT Classification code 10009013 Term: Chronic myeloid leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Belgium, Finland, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United States
- 2014-05-21
Authorised
- An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy. - Zalutumumab in non-curable Patients with SCCHN
- Non-Curable Squamous Cell Carcinoma of the Head and Neck (SCCHN) MedDRA version: 9.1 Level: LLT Classification code 10060121 Term: Squamous cell carcinoma of head and neck
- Austria, Czech Republic, Germany, Italy, Portugal, Slovakia
- 2008-06-19